Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.
Bicara Therapeutics Inc. is launching an at-the-market offering of up to $150,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on The Nasdaq Global Market under the symbol BCAX, in negotiated transactions or other methods deemed to be at-the-market offerings, with TD Cowen earning a commission of up to 3.0% of gross proceeds.
Bicara is a clinical-stage biopharmaceutical company focused on bifunctional antibodies for solid tumors. Its lead program, ficerafusp alfa, is in a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma, following Phase 1/1b data showing a 54% objective response rate and 21.3‑month median overall survival in an efficacy-evaluable HPV‑negative population. Net proceeds are expected to support research and clinical development, commercialization preparation, expansion of R&D programs, and general corporate purposes.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Financial Officer on Form 4. On November 21, 2025, the CFO exercised 605 stock options at $3.7898 per share and sold 605 shares of common stock at a price of $18.15 per share. On November 24, 2025, the CFO exercised an additional 17,795 options at $3.7898 and sold 17,795 shares at a weighted average price of $18.5498, with sales occurring between $18.15 and $18.84. After these trades, the CFO beneficially owned 145,355 shares of common stock directly and held 98,184 stock options. The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025.
Bicara Therapeutics Inc. insider transaction: On 11/21/2025, a reporting person who is both a director and the President and COO of Bicara Therapeutics Inc. (BCAX) exercised a stock option for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold shares of common stock on the same day.
The insider reported selling 8,000 shares of common stock at a weighted average price of $18.047 per share and an additional 4,500 shares at the same weighted average price, executed in multiple trades between $18.00 and $18.14. After these transactions, the insider beneficially owned 193,641 shares of common stock directly and 149,334 stock options. The option for 8,000 shares was granted on August 8, 2023 and vests in sixteen equal quarterly installments, contingent on continued service, and was exercised under a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX) reported an insider transaction by its Chief Executive Officer, who is also a director. On 11/24/2025, the reporting person exercised stock options for 41,163 shares of common stock at an exercise price of $3.7898 per share and then sold 41,163 shares of common stock at a weighted average price of $18.8623 per share under transaction code "S".
The option exercised is a stock option (right to buy) covering 41,163 shares of common stock, with an exercise price of $3.7898, expiring on 08/08/2033. The filing states that these option shares vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service. After the reported transactions, the reporting person beneficially owns 309,892 shares of common stock and 236,107 stock options, all held directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Medical Officer, who filed a Form 4 as a single reporting person. On 11/24/2025 and 11/25/2025, the officer exercised stock options to acquire common shares at an exercise price of $3.7898 per share and sold the same number of shares on each corresponding date.
On 11/24/2025, 5,500 shares of common stock were acquired through an option exercise and 5,500 shares were sold at $18.45 per share, leaving 35,497 shares owned directly. On 11/25/2025, additional option exercises and sales covered 4,594 and 906 shares, with sales at a weighted average price of $18.8424. After these transactions, the officer directly owned 35,497 common shares and held stock options covering 69,413 shares, subject to the vesting schedules described.
The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on February 12, 2025, with certain sale prices reported as weighted averages across multiple individual transactions.
Bicara Therapeutics (BCAX) reported Q3 2025 results with a net loss of $36.3 million as operating expenses rose to $40.7 million on increased R&D. Research and development totaled $33.0 million (including related-party), reflecting ongoing spend for ficerafusp alfa and the FORTIFI-HN01 program.
Cash, cash equivalents and investments were $407.6 million as of September 30, 2025, supported by short- and long-term U.S. Treasury holdings. Net cash used in operating activities was $82.9 million for the nine months, while interest income contributed $4.4 million in the quarter. The company reported an accumulated deficit of $321.6 million.
Management states existing liquidity is expected to fund operations into the first half of 2029. As a subsequent event, Bicara filed a Form S-3 shelf for up to $400.0 million and established an ATM program of up to $150.0 million; no sales have occurred. Shares outstanding were 54,781,950 as of November 5, 2025.
Bicara Therapeutics (BCAX) furnished an 8-K announcing it issued a press release with financial results and business highlights for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities. BCAX common stock trades on The Nasdaq Global Market.
Bicara Therapeutics (BCAX) CEO reported a Form 4 for transactions on October 16, 2025. The executive exercised 24,103 stock options at $3.7898 per share and sold 24,103 common shares at a $18.8259 weighted average price, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the reporting person beneficially owns 309,892 common shares directly and 277,270 derivative securities (options) remain beneficially owned. The sale price ranged from $18.73 to $19.17. The option underlying the exercised shares vests in sixteen equal quarterly installments following August 8, 2023.
Bicara Therapeutics (BCAX) reported insider transactions by its President & COO (also a Director) on 10/15/2025. The officer exercised a stock option for 8,000 shares at an exercise price of $3.7898 and then sold 8,000 shares and an additional 4,500 shares at a weighted average price of $18.1554 (sales occurred between $18.00 and $18.34), executed pursuant to a Rule 10b5‑1 trading plan adopted on February 12, 2025.
Following these transactions, the reporting person beneficially owned 198,141 shares of common stock directly and held 157,334 derivative securities (stock options). The reported option was granted with a term through 08/08/2033 and vests in sixteen equal quarterly installments following 08/08/2023, subject to continued service.